Introduction

Liposem 2 mg (Saroglitazar Magnesium) Tablet is a pioneering dual peroxisome proliferator-activated receptor (PPAR) agonist designed to manage diabetic dyslipidemia and hypertriglyceridemia in patients with Type 2 diabetes mellitus inadequately controlled by statins. Manufactured by Everest Pharmaceuticals Ltd., a WHO-GMP-certified leader in metabolic disorder therapies, and supplied globally by Onco Solution, Liposem 2 mg (Saroglitazar Magnesium) Tablet addresses both lipid abnormalities and glycemic imbalances. By targeting PPAR-α and PPAR-γ pathways, it reduces triglycerides (TG), improves cholesterol profiles, and enhances glucose metabolism, offering a comprehensive solution for patients with complex metabolic needs.

Key Benefits & Mechanism of Action

Liposem 2 mg (Saroglitazar Magnesium) Tablet combines PPAR-α and PPAR-γ agonistic activity to deliver dual metabolic benefits:

1. Lipid Control:
   • PPAR-α Activation: Enhances fatty acid oxidation in the liver, reduces TG synthesis, and lowers LDL, VLDL, and non-HDL cholesterol.
   • Lipoprotein Lipase (LPL) Stimulation: Promotes breakdown of TG-rich particles and reduces apolipoprotein C-III (inhibitor of LPL), clearing triglycerides from plasma.
   • HDL Boost: Increases apolipoproteins A-I/A-II, raising HDL cholesterol levels.
2. Glycemic Management:
   • PPAR-γ Activation: Regulates insulin-responsive genes, improving glucose uptake and reducing hepatic glucose output.
   • Adiponectin Upregulation: Enhances insulin sensitivity and reduces postprandial free fatty acids.

Indications

Liposem 2 mg (Saroglitazar Magnesium) Tablet is approved for:

• Diabetic Dyslipidemia: Management of elevated TG, LDL, and non-HDL cholesterol in Type 2 diabetes patients unresponsive to statins.
• Hypertriglyceridemia: Reduction of severely high triglyceride levels to prevent pancreatitis and cardiovascular risks.

Pharmacology

Saroglitazar, the active ingredient, exerts its effects through nuclear receptor modulation:

• PPAR-α Dominance: Drives lipid metabolism by increasing hepatic fatty acid oxidation and reducing TG secretion.
• PPAR-γ Modulation: Improves insulin sensitivity via genes like adiponectin, CD36, and LPL, facilitating glucose utilization.
• Clinical Outcomes: In trials, Liposem 2 mg (Saroglitazar Magnesium) Tablet reduced fasting glucose, HbA1c, and TG by 45-50%, while increasing HDL by 10-15%.

Dosage & Administration

• Adults: 4 mg daily (two 2 mg tablets once daily).
• Pediatric Use: Not recommended for patients under 18 years (safety unestablished).
• Geriatric Patients: Use with caution due to comorbidities and polypharmacy risks.

Drug Interactions

• Cytochrome P450 Enzymes: No significant inhibition/induction of CYP1A2, 2C9, 2C19, 2D6, or 3A4 at therapeutic doses.
• Clinical Relevance: Low risk of interactions with statins, antidiabetics, or anticoagulants.

Contraindications

• Hypersensitivity to Saroglitazar or excipients.

Side Effects

Common Reactions:

• Gastritis (mild to moderate), asthenia (weakness), pyrexia (fever).
  Rare Reactions:
• Elevated liver enzymes, fluid retention, hypoglycemia.

Pregnancy & Lactation

• Pregnancy Category C: Risk to fetus unknown; use only if benefits outweigh risks.
• Lactation: Avoid breastfeeding—no data on drug excretion in milk.

Precautions & Warnings

• Hepatic/Renal Impairment: Monitor liver/kidney function periodically.
• Cardiac Patients: Watch for fluid retention or congestive heart failure exacerbation.
• Weight Gain: Assess for edema or volume-related complications.

Overdose Management

No reported cases. Supportive care includes vital sign monitoring and symptom management.

Storage & Handling

Store below 30°C in original packaging, protected from light and moisture. Keep away from children.

Manufacturer & Supplier

Everest Pharmaceuticals Ltd.: Innovators in metabolic health, Everest’s WHO-GMP-certified facilities ensure rigorous quality standards.
Onco Solution: Trusted global distributor for Liposem 2 mg (Saroglitazar Magnesium) Tablet. For orders, visit www.oncosolution.com.

Conclusion

Liposem 2 mg (Saroglitazar Magnesium) Tablet redefines management of diabetic dyslipidemia by synergistically targeting lipid and glucose metabolism. Its dual PPAR-α/γ agonism offers a unique advantage for statin-resistant patients, improving both cardiovascular and diabetic outcomes. Trust Everest Pharmaceuticals Ltd. for cutting-edge therapy and Onco Solution for seamless global access. For clinical or procurement inquiries, contact Onco Solution today.